Windward Bio Group AG (NASDAQ:WWB – Get Free Report) Director Orbimed Advisors Llc acquired 1,176,471 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $20,000,007.00. Following the completion of the acquisition, the director directly owned 1,708,103 shares of the company’s stock, valued at $29,037,751. The trade was a 221.29% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Windward Bio Group Stock Up 1.1%
NASDAQ:WWB opened at $24.28 on Friday. Windward Bio Group AG has a fifty-two week low of $18.35 and a fifty-two week high of $33.99.
Windward Bio Group Company Profile
Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Further Reading
- Five stocks we like better than Windward Bio Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Windward Bio Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windward Bio Group and related companies with MarketBeat.com's FREE daily email newsletter.
